naproxen sodium

(redirected from Bystolic)
Also found in: Dictionary, Medical, Wikipedia.
Related to Bystolic: Nebivolol, Crestor
  • noun

Synonyms for naproxen sodium

a nonsteroidal anti-inflammatory drug (trademarks Aleve and Anaprox and Aflaxen) that fights pain and inflammation

References in periodicals archive ?
maker of generic drugs, said profit rose 15% on the sale of rights to the blood pressure drug Bystolic and on revenue from acquisitions.
Commercially we have successfully launched five new products in less than five years - Bystolic, Savella, Teflaro, Daliresp and Viibryd.
In addition, contemporaneously with the closing of the acquisition, Forest and Janssen terminated the licenses in Canada for both Bystolic and Savella([R]) (milnacipran) with Janssen Pharmaceutica NV and Janssen Pharmaceutical, respectively.
6 million in quarterly sales representing 33% growth over the prior year is truly an outstanding performance, particularly since Bystolic is the only branded beta-blocker in an otherwise generic category of multiple anti-hypertensive agents.
We also continue to see solid performance for Bystolic, Savella and Teflaro.
The current level of spending reflects the resources and activities required to support our currently marketed products, particularly our newest products, Bystolic, Savella and Teflaro, as well as launch activities related to Daliresp and Viibryd.
Mylan and Forest Labs Win FDA Approval to Market Bystolic II-113
In just the past 38 months, Forest has obtained five product approvals from five different divisions of the FDA and has launched Bystolic, Savella, Teflaro, Daliresp and Viibryd.
Azimilide could be the first agent to be approved specifically for this patient population in the United States and would be prescribed, if approved, by many physicians who also prescribe our beta blocker Bystolic for the treatment of hypertension.
Bystolic was launched in January 2008, and sales in last year's fiscal fourth quarter were $53.
The agency's outside panel of heart specialists voted 8-0 against approving Bystolic to prevent death or hospitalization caused by heart failure, according to an FDA spokeswoman.
Comment: In three monotherapy trials of more than 2,000 patients, and one combination therapy trial of almost 700 patients, the blood pressure-lowering effects of Bystolic were in the high single digits, which is comparable with other [beta]-blockers, although not to the degree expected with a diuretic or calcium blocker, said Dr.